Business
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced
About this update from Atyr Pharma, Inc.
[{"type":"image","alt":"aTyr Pharma, Inc.","displaySize":"","headline":null,"caption":"aTyr Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/9b5f13b39204584ce149705b65740791"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3m4LnsxUZVB.dx6N.MAnrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9b5f13b39204584ce149705b65740791","width":300,"height":179}},"lazy":false},{"type":"text","content":"Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1.","length":103,"tagName":"p"},{"type":"text","content":"ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit.","length":120,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has advanced its next investigational new drug (IND) candidate, ATYR0101, which has been selected to be showcased in an oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit, which is scheduled to take place May 16 – 17, 2025, in San Francisco, CA.","length":569,"tagName":"p"},{"type":"text","content":"The presentation will feature preclinical data generated to date for ATYR0101, a fusion protein derived from a proprietary extracellular domain of aspartyl-tRNA synthetase (DARS) that binds to latent transforming growth factor beta binding protein 1 (LTBP-1) to induce cell death of myofibroblasts, which are key cells responsible for driving the progression of fibrosis.","length":371,"tagName":"p"},{"type":"text","content":"“Fibrosis is a key driver of morbidity and mortality in many diseases, particularly those affecting the lung, where evasion of myofibroblast cell death is a defining feature,” said Leslie A. Nangle, Ph.D., Vice President, Research, at aTyr. “The unique effects observed with ATYR0101 in preclinical models of fibrosis suggest it may have the potential to reverse fibrosis, which could represent a meaningful advancement in the approach to treating pulmonary...